A recent example of the impact of nanomedicine in drug delivery is underscored by the success of AbraxaneTM, an albumin nanoparticle conjugate of paclitaxel, and the first FDA-approved anti-cancer agent in this emerging class of drug formulations [39]. Here, ALB is linked to cancer.